Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AngLT-1: Angiotensin II in Liver Transplantation
NCT04901169Phase 3Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Angiotensin II in Vasoplegia (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Total dose of norepinephrine at 8 hours. Started Jun 2022; status: active, not recruiting.
02
Drugs
Angiotensin II
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on NCT04901169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901169.